Chile · Delayed Price · Currency is CLP Inversiones La Construcción Earnings Call Transcripts
Fiscal Year 2026
-
H1 profit rose 44.7% to CLP 160 billion, with stronger banking, pensions and healthcare. Acquisition-led RedSalud growth and improved bank earnings were partly offset by weaker Confuturo investments and a one-time health-insurance charge.
-
Q1 profit rose 125% YoY to CLP 89.1 billion, with stronger banking, investment and healthcare results. RedSalud’s acquisition expanded its network, while debt-to-equity stood at 0.31x.
Fiscal Year 2025
-
FY25 record profit reached CLP 280 billion, up 89% YoY, with 23.4% ROE. Q4 growth across subsidiaries was led by strong investment results, healthcare activity, and Banco Internacional loan growth.
-
Q3 profit rose 25% YoY to CLP 72.4 billion, with stronger financial markets and subsidiary performance. Consalud’s non-cash CLP 18.3 billion valuation loss partly offset gains; Fitch upgraded the rating to BBB+.
-
Consolidated Q2 profit rose 195% YoY to CLP 74.5 billion as markets rebounded and financial subsidiaries recovered. Healthcare revenue and EBITDA grew, while elevated credit provisions and Vida Cámara claims costs remained pressures.
-
Q1 net profit fell 33.2% YoY to CLP 39.6bn as global market volatility weakened investment returns, partly offset by stronger banking and healthcare operations. Loan growth, annuity demand and liquidity remained supportive, while pension reform and credit costs are key watchpoints.
Fiscal Year 2024
-
FY24 net profit was CLP 148.2bn after the Short Law accounting effect. Banking, annuity and healthcare operations posted growth, while Consalud’s IFRS liability and lower revenues weighed on results; pension reform and diversified funding shape the outlook.
-
Q3 profit rose nearly 62% YoY to CLP 57.8 billion, led by financial subsidiaries. RedSalud grew EBITDA and margin, while Consalud remained pressured by lower GES premiums and fewer beneficiaries.
-
Q2 profit was CLP 25.2 billion before Consalud’s Ley Corta adjustment, as stronger financial subsidiaries were offset by weaker markets and health-insurance losses. RedSalud EBITDA grew 14.7% YoY, while net financial debt to equity remained 0.3x.
-
Q1 net income reached CLP 59.3bn, nearly 70% higher YoY, led by financial subsidiaries and stronger investment returns. Loan growth and RedSalud’s improved operating performance were offset in part by Consalud’s GES-related revenue decline.
Fiscal Year 2023
-
Recurring 2023 earnings reached a record CLP 182.6 billion, with ROE close to 20%, supported by stronger banking and annuity businesses. Growth plans center on Banco Internacional and Confuturo, while pension and health reforms remain key uncertainties.
-
After a decade of diversification, the focus shifts to growth across banking, annuities, pensions and health. Targets include doubling bank loans and reaching CLP 85–100bn bank profit by 2027, alongside around CLP 80bn in Confuturo profit.
-
Q1 profit was CLP34.9b, led by financial subsidiaries, while trailing 12-month profit reached CLP157.3b at 18% ROE. Healthcare revenue and activity grew, but RedSalud margins weakened and health-insurance outlook remained uncertain.